Skip to main content
Top
Published in: Familial Cancer 1/2016

Open Access 01-01-2016 | Original Article

Germline TERT promoter mutations are rare in familial melanoma

Authors: Mark Harland, Mia Petljak, Carla Daniela Robles-Espinoza, Zhihao Ding, Nelleke A. Gruis, Remco van Doorn, Karen A. Pooley, Alison M. Dunning, Lauren G. Aoude, Karin A. W. Wadt, Anne-Marie Gerdes, Kevin M. Brown, Nicholas K. Hayward, Julia A. Newton-Bishop, David J. Adams, D. Timothy Bishop

Published in: Familial Cancer | Issue 1/2016

Login to get access

Abstract

Germline CDKN2A mutations occur in 40 % of 3-or-more case melanoma families while mutations of CDK4, BAP1, and genes involved in telomere function (ACD, TERF2IP, POT1), have also been implicated in melanomagenesis. Mutation of the promoter of the telomerase reverse transcriptase (TERT) gene (c.−57 T>G variant) has been reported in one family. We tested for the TERT promoter variant in 675 multicase families wild-type for the known high penetrance familial melanoma genes, 1863 UK population-based melanoma cases and 529 controls. Germline lymphocyte telomere length was estimated in carriers. The c.−57 T>G TERT promoter variant was identified in one 7-case family with multiple primaries and early age of onset (earliest, 15 years) but not among population cases or controls. One family member had multiple primary melanomas, basal cell carcinomas and a bladder tumour. The blood leukocyte telomere length of a carrier was similar to wild-type cases. We provide evidence confirming that a rare promoter variant of TERT (c.−57 T>G) is associated with high penetrance, early onset melanoma and potentially other cancers, and explains <1 % of UK melanoma multicase families. The identification of POT1 and TERT germline mutations highlights the importance of telomere integrity in melanoma biology.
Appendix
Available only for authorised users
Literature
1.
go back to reference Horn S, Figl A, Rachakonda PS et al (2013) TERT promoter mutations in familial and sporadic melanoma. Science 339(6122):959–961PubMedCrossRef Horn S, Figl A, Rachakonda PS et al (2013) TERT promoter mutations in familial and sporadic melanoma. Science 339(6122):959–961PubMedCrossRef
2.
go back to reference Gandini S, Sera F, Cattaruzza MS et al (2005) Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 41(14):2040–2059PubMedCrossRef Gandini S, Sera F, Cattaruzza MS et al (2005) Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 41(14):2040–2059PubMedCrossRef
3.
go back to reference Gandini S, Sera F, Cattaruzza MS et al (2005) Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 41(1):28–44PubMedCrossRef Gandini S, Sera F, Cattaruzza MS et al (2005) Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 41(1):28–44PubMedCrossRef
4.
go back to reference Barrett JH, Iles MM, Harland M et al (2011) Genome-wide association study identifies three new melanoma susceptibility loci. Nat Genet 43(11):1108–1113PubMedPubMedCentralCrossRef Barrett JH, Iles MM, Harland M et al (2011) Genome-wide association study identifies three new melanoma susceptibility loci. Nat Genet 43(11):1108–1113PubMedPubMedCentralCrossRef
5.
go back to reference Goldstein AM, Chan M, Harland M et al (2007) Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 44(2):99–106PubMedPubMedCentralCrossRef Goldstein AM, Chan M, Harland M et al (2007) Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 44(2):99–106PubMedPubMedCentralCrossRef
6.
go back to reference Helgadottir H, Höiom V, Jönsson G et al (2014) High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families. J Med Genet 51(8):545–552PubMedPubMedCentralCrossRef Helgadottir H, Höiom V, Jönsson G et al (2014) High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families. J Med Genet 51(8):545–552PubMedPubMedCentralCrossRef
7.
go back to reference Potrony M, Puig-Butillé JA, Aguilera P et al (2014) Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling. J Am Acad Dermatol 71(5):888–895PubMedPubMedCentralCrossRef Potrony M, Puig-Butillé JA, Aguilera P et al (2014) Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling. J Am Acad Dermatol 71(5):888–895PubMedPubMedCentralCrossRef
8.
go back to reference Puntervoll HE, Yang XR, Vetti HH et al (2013) Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. J Med Genet 50(4):264–270PubMedPubMedCentralCrossRef Puntervoll HE, Yang XR, Vetti HH et al (2013) Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. J Med Genet 50(4):264–270PubMedPubMedCentralCrossRef
9.
go back to reference Carbone M, Ferris LK, Baumann F et al (2012) BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med 10:179PubMedPubMedCentralCrossRef Carbone M, Ferris LK, Baumann F et al (2012) BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med 10:179PubMedPubMedCentralCrossRef
11.
12.
13.
go back to reference Burke LS, Hyland PL, Pfeiffer RM et al (2013) Telomere length and the risk of cutaneous malignant melanoma in melanoma-prone families with and without CDKN2A mutations. PLoS One 8(8):e71121PubMedPubMedCentralCrossRef Burke LS, Hyland PL, Pfeiffer RM et al (2013) Telomere length and the risk of cutaneous malignant melanoma in melanoma-prone families with and without CDKN2A mutations. PLoS One 8(8):e71121PubMedPubMedCentralCrossRef
14.
go back to reference Aoude LG, Pritchard AL, Robles-Espinoza CD et al (2015) Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma. J Natl Cancer Inst 107(2):dju408PubMedCrossRef Aoude LG, Pritchard AL, Robles-Espinoza CD et al (2015) Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma. J Natl Cancer Inst 107(2):dju408PubMedCrossRef
15.
go back to reference Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA (2013) Highly recurrent TERT promoter mutations in human melanoma. Science 339(6122):957–959PubMedPubMedCentralCrossRef Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA (2013) Highly recurrent TERT promoter mutations in human melanoma. Science 339(6122):957–959PubMedPubMedCentralCrossRef
16.
go back to reference Iles MM, Bishop DT, Taylor JC et al (2014) The effect on melanoma risk of genes previously associated with telomere length. J Natl Cancer Inst 106(10):dju267CrossRef Iles MM, Bishop DT, Taylor JC et al (2014) The effect on melanoma risk of genes previously associated with telomere length. J Natl Cancer Inst 106(10):dju267CrossRef
17.
go back to reference Newton-Bishop JA, Chang YM, Iles MM et al (2010) Melanocytic nevi, nevus genes, and melanoma risk in a large case-control study in the United Kingdom. Cancer Epidemiol Biomark Prev 19(8):2043–2054CrossRef Newton-Bishop JA, Chang YM, Iles MM et al (2010) Melanocytic nevi, nevus genes, and melanoma risk in a large case-control study in the United Kingdom. Cancer Epidemiol Biomark Prev 19(8):2043–2054CrossRef
19.
go back to reference Ding Z, Mangino M, Aviv A, Spector T, Durbin R, Consortium UK (2014) Estimating telomere length from whole genome sequence data. Nucleic Acids Res 42(9):e75PubMedPubMedCentralCrossRef Ding Z, Mangino M, Aviv A, Spector T, Durbin R, Consortium UK (2014) Estimating telomere length from whole genome sequence data. Nucleic Acids Res 42(9):e75PubMedPubMedCentralCrossRef
20.
21.
go back to reference Weinhold N, Jacobsen A, Schultz N, Sander C, Lee W (2014) Genome-wide analysis of noncoding regulatory mutations in cancer. Nat Genet 46(11):1160–1165PubMedPubMedCentralCrossRef Weinhold N, Jacobsen A, Schultz N, Sander C, Lee W (2014) Genome-wide analysis of noncoding regulatory mutations in cancer. Nat Genet 46(11):1160–1165PubMedPubMedCentralCrossRef
22.
go back to reference Hsu CP, Hsu NY, Lee LW, Ko JL (2006) Ets2 binding site single nucleotide polymorphism at the hTERT gene promoter–effect on telomerase expression and telomere length maintenance in non-small cell lung cancer. Eur J Cancer 42(10):1466–1474PubMedCrossRef Hsu CP, Hsu NY, Lee LW, Ko JL (2006) Ets2 binding site single nucleotide polymorphism at the hTERT gene promoter–effect on telomerase expression and telomere length maintenance in non-small cell lung cancer. Eur J Cancer 42(10):1466–1474PubMedCrossRef
Metadata
Title
Germline TERT promoter mutations are rare in familial melanoma
Authors
Mark Harland
Mia Petljak
Carla Daniela Robles-Espinoza
Zhihao Ding
Nelleke A. Gruis
Remco van Doorn
Karen A. Pooley
Alison M. Dunning
Lauren G. Aoude
Karin A. W. Wadt
Anne-Marie Gerdes
Kevin M. Brown
Nicholas K. Hayward
Julia A. Newton-Bishop
David J. Adams
D. Timothy Bishop
Publication date
01-01-2016
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 1/2016
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-015-9841-9

Other articles of this Issue 1/2016

Familial Cancer 1/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine